Full video transcriptClick to expand
Auto-generated transcript of @matthearenteamd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Everything on here is informational, so please make sure that you talk to your doctor,
- 0:03then I'm gonna talk in broad strokes for a second. This question says I've been on it for a month and
- 0:08a half and I can barely eat anything or sip water. I'm so weak on 6-6-1.8. 6-6 is a daily
- 0:16medication. It starts at 0.6 milligrams and the just like what the general prescribing recommendations are
- 0:23that you go up weekly by 0.6 until you get to a max dose of 3 milligrams. This is the thing.
- 0:29You need to be in close contact with your physician because not everybody is going to follow the same
- 0:34titration protocol and it's four reasons like this. This is why we can't do the one-size-fits-all
- 0:40where we just give you the medicine and we're like bye see you back in three months because of stuff
- 0:44like this. I feel so bad the fact that you are feeling so weak and can't eat and can't drink. That's
- 0:51not normal, not normal, not what we're going for. We want with these medicines a little bit of appetite
- 0:57suppression, a little bit of helping you out, not such that you can't eat and drink and you're feeling
- 1:01weak, not normal. Please talk to your doctor. One of the things with the medicine like this with
- 1:06any of these where we have these different titration doses. Again, sicenda is weekly going up on the
- 1:11dose. Other ones, it's monthly so you'll be for four weeks at something and then hopefully your
- 1:16doctor checks in with you around week three or four and sees with the refill. Do you stay the same?
- 1:21Do you go up and there's logic that goes into it. How much are you losing? Where's your appetite
- 1:26suppression at? What are your side effects like? There's a lot that goes into the logic of it.
- 1:31There's a reason. Reason to go up and then there's reason to stay right where you're at and often
- 1:36if you are not tolerating things. So week after week, these symptoms usually get better with the
- 1:41GLP ones. They usually start to go down. But if that's not happening, there's a problem and your
- 1:47doctor needs to be informed so that your doctor can help you out. Do you decrease it? Do you stop it?
- 1:51That's a decision between you and your doctor. Everybody hear me when I say if you're sitting there
- 1:56and you can't tolerate oral intake, not normal. I just want to say that not normal, not normal,
- 2:03not normal, not the goal, not how these meds are meant to be used. No, no, no, no, no. Okay,
- 2:09that's the message for today. And I realize I keep forgetting to throw this part in. If you live in
- 2:12Indiana or Illinois and you want a physician that can help you with this, hi, I'm here. So if
- 2:17you want to find out more, I'll put my clinic information down here. But what I want to say,
- 2:21one of the things that I do in my clinic that's different, you just have a lot more access to me.
- 2:24There's not like a million in between people. I run what's called a direct care obesity medicine
- 2:29practice, meaning it's me and you, it's you and the dietitian. We've got groups, we've got videos to
- 2:35watch. We have just a comprehensive program where you're not left with medication in the wild where
- 2:40you're feeling like crap and no one's following up with you.
Saxenda for weight loss: what an MD on TikTok is likely telling you
Quick answer
The viewer described on liraglutide (Saxenda) 1.8 mg daily after approximately six weeks on therapy with inability to tolerate oral fluids and significant weakness, which are symptoms consistent with dehydration secondary to GLP-1-related gastrointestinal adverse effects and warrant same-day clinical evaluation, possible dose reduction, and assessment of hydration status. Liraglutide's weekly titration schedule (0.6 mg increments up to 3 mg daily) is FDA-approved, but the label supports holding or reducing the dose when tolerability is compromised. This case illustrates why individualized follow-up during dose escalation is clinically necessary, not optional.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda for weight loss: what an MD on TikTok is likely telling you, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda for weight loss: what an MD on TikTok is likely telling you is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Saxenda for weight loss: what an MD on TikTok is likely telling you" from Matthea Rentea MD. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The viewer described on liraglutide (Saxenda) 1.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to corinnamora saxenda glp1 glp1medications illinoi." In this clip, the useful excerpt is: "Everything on here is informational, so please make sure that you talk to your doctor, then I'm gonna talk in broad strokes for a second." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The viewer described on liraglutide (Saxenda) 1.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The viewer described on liraglutide (Saxenda) 1.8 mg daily after approximately six weeks on therapy with inability to tolerate oral fluids and significant weakness, which are symptoms consistent with dehydration secondary to GLP-1-related gastrointestinal adverse effects and warrant same-day clinical evaluation, possible dose reduction, and assessment of hydration status. Liraglutide's weekly titration schedule (0.6 mg increments up to 3 mg daily) is FDA-approved, but the label supports holding or reducing the dose when tolerability is compromised. This case illustrates why individualized follow-up during dose escalation is clinically necessary, not optional.
- The FDA-approved Saxenda titration is 0.6 mg daily in week one, increasing by 0.6 mg each week, with a 3 mg daily maintenance target. The label explicitly supports dose reduction if side effects are not tolerable.
- In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM), about 32% of liraglutide patients experienced nausea versus 10% on placebo. Most was transient, but a meaningful minority discontinued due to persistent intolerance.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The FDA-approved Saxenda titration is 0.6 mg daily in week one, increasing by 0.6 mg each week, with a 3 mg daily maintenance target. The label explicitly supports dose reduction if side effects are not tolerable.
- In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM), about 32% of liraglutide patients experienced nausea versus 10% on placebo. Most was transient, but a meaningful minority discontinued due to persistent intolerance.
- Inability to tolerate oral fluids is not a normal GLP-1 side effect. It carries risk of dehydration and secondary complications including acute kidney injury, and requires same-day contact with a prescriber.
- Different GLP-1 medications use different titration intervals. Liraglutide (Saxenda) escalates weekly. Semaglutide and tirzepatide use four-week intervals per their FDA labels.
- Slower titration than the label schedule is used in clinical practice to manage tolerability, though large randomized trial evidence specifically supporting extended titration intervals is limited.
- The AACE/ACE 2016 obesity management guidelines support a comprehensive care model with active follow-up during pharmacotherapy, not a prescribe-and-disappear approach.
- If you are on a GLP-1 medication and cannot keep water down or feel physically weak, contact your prescriber the same day. Do not interpret general reassurance that symptoms 'usually improve' as a reason to wait.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @matthearenteamd actually say?
The creator, who identifies as an MD running a direct-care obesity medicine practice, was responding to a viewer who said they had been on Saxenda (liraglutide) for a month and a half, had just reached the 1.8 mg dose, and could "barely eat anything or sip water" and felt extremely weak. The doctor's message was unambiguous: "not normal, not normal, not what we're going for." They walked through the standard liraglutide titration schedule, starting at 0.6 mg daily and increasing weekly by 0.6 mg toward a 3 mg maximum. Their core argument was that severe intolerance like this is a clinical signal that demands physician follow-up, not something patients should push through alone. They also noted that titration protocols vary between GLP-1 medications, with some moving monthly rather than weekly, and that dosing decisions should be individualized based on weight loss, side effects, and appetite suppression.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Matthea Rentea MD · TikTok creator
66.7K views on this video
Replying to @corinnamora #saxenda #glp1 #glp1medications #illinois #indiana #md
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the fda-approved saxenda titration?
The FDA-approved Saxenda titration is 0.6 mg daily in week one, increasing by 0.6 mg each week, with a 3 mg daily maintenance target. The label explicitly supports dose reduction if side effects are not tolerable.
What does the video say about in the scale obesity?
In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM), about 32% of liraglutide patients experienced nausea versus 10% on placebo. Most was transient, but a meaningful minority discontinued due to persistent intolerance.
What does the video say about inability to tolerate?
Inability to tolerate oral fluids is not a normal GLP-1 side effect. It carries risk of dehydration and secondary complications including acute kidney injury, and requires same-day contact with a prescriber.
What does the video say about different glp-1 medications use different titration intervals. liraglutide (saxenda) escalates?
Different GLP-1 medications use different titration intervals. Liraglutide (Saxenda) escalates weekly. Semaglutide and tirzepatide use four-week intervals per their FDA labels.
What does the video say about slower titration than the label schedule?
Slower titration than the label schedule is used in clinical practice to manage tolerability, though large randomized trial evidence specifically supporting extended titration intervals is limited.
What does the video say about the aace/ace 2016 obesity management guidelines support a comprehensive care?
The AACE/ACE 2016 obesity management guidelines support a comprehensive care model with active follow-up during pharmacotherapy, not a prescribe-and-disappear approach.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Matthea Rentea MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.